1. Neratinib plus dasatinib has pre-clinical efficacy against HER2-positive breast cancer. (October 2022) Authors: Conlon, N.; Roche, S.; O'Neill, F.; Meiller, J.; Browne, A.; Breen, L.; O'Driscoll, L.; Cremona, M.; Hennessy, B.; Crown, J.; Collins, D. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗